mProX™ Human NEK3 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

NEK3, a member of the NEK (Never in mitosis A related kinase) gene family, has been found to have differential expression in various types of cancers. In esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE), NEK3 is significantly upregulated, suggesting its potential role in tumorigenesis and progression of EAC. In prostate cancer, BRCA2-deficient tumors exhibit enriched homozygous deletions at NEK3, indicating its involvement in the etiology and prognosis of BRCA2-deficient prostate tumors. In breast cancer, different NEK family members show distinct expression patterns and prognostic values. NEK2, NEK6, and NEK11 are significantly highly expressed in breast cancer, while NEK1, NEK3, NEK8, NEK9, NEK10, and NEK11 are associated with better prognosis. NEKs have also been explored as potential biomarkers for cancer and as therapeutic targets, with some NEK inhibitors reported in the literature. Additionally, NEKs, including NEK2, NEK3, NEK4, NEK7, and NEK9, have been induced in the lungs of mice with sepsis, suggesting their involvement in inflammatory processes and potential as therapeutic targets for conditions such as acute respiratory distress syndrome (ARDS) and sepsis. Overall, NEK3 and other NEK family members have emerged as important players in cancer development, prognosis, and potential therapeutic interventions.